BRO Thesis Assessment
Brown & Brown, Inc.
BRO's market price of $65.90 appears to be below the fundamental value indicated by this analysis.
Q1 2026 produced a mixed but overall thesis-supportive update. Organic Revenue grew 0.0% (resolves the Q1 organic >3% market NO at Brier 0.270) — a meaningful negative against the 'modest improvement over 2.8%' guide and the 0.52 prior probability. However, Adjusted EBITDAC margin expanded 40 bps to 38.5%, Adjusted EPS grew 7.8% to $1.39, operating cash flow grew 23% to $262M, and management deployed $250M in share repurchases (50% of the FY26 $500M market threshold in a single quarter). Net of resolved + active markets, the durability ensemble (margin floor 84% pre-Q1, dividend continuity 96%, Howden $50M+ at 25%) remains intact, while the cyclical-organic ensemble has weakened. The 44% drawdown was partly justified by genuine cyclical pressures that Q1 confirmed are real, but the magnitude of margin/capital strength continues to disconnect from a 'broken business' interpretation. price-below-value classification holds with reduced conviction — the asymmetry is now narrower (downside floor strengthened by capital deployment + margin durability; upside requires Q2/H2 organic recovery evidence rather than the pre-earnings cadence beat that was already priced).
What the Markets Suggest
Q1 2026 was the first hard test of BRO's pre-earnings thesis, and the results split cleanly across the durability and cyclical legs. The durability leg strengthened: Adjusted EBITDAC margin expanded 40 bps to 38.5% in the seasonally peak quarter, Adjusted EPS grew 7.8% to $1.39, operating cash flow rose 23% to $262M, and management executed $250M of share repurchases — half of the FY26 $500M market threshold in a single quarter. These outcomes confirm the FY26 ≥32% margin market (84% prior) is well-founded and re-price the FY26 buyback ≥$500M market substantially higher. The dividend remained at $0.165 (annual increase historically announced on the Q3 call), consistent with 33-year streak continuation at 96% probability.
The cyclical leg weakened. Organic Revenue grew 0.0% in Q1 — flat against Q1 2025 — well below the 3.0% market threshold (resolves NO at Brier 0.270) and below the 'modest improvement over 2.8%' implied FY26 guide. Q1 was supposed to be the easiest quarter of 2026: it followed Q4 2025's -2.8% organic trough and arrived before tighter casualty rate comps in H2. The 0.0% print suggests either H1 2026 stays at-or-near zero organic (substantially below the implied guide) or the recovery is materially back-loaded into Q3-Q4 as Howden runs off and CAT property finds a floor. Three drivers contributed: continued CAT property soft cycle (-15-30% rates), $10M of Howden Litigation-Related Impact (cumulative ~$33M, accelerating toward the $50M market threshold), and tough comp vs Q1 2025's 6.5%.
The FY26 organic above 4% market (32% prior probability) is now meaningfully harder. Clearing 4% would require average organic growth of ~5.3% across Q2-Q4 — a substantial acceleration from zero — achievable only if Howden runoff completes, CAT pricing bottoms, and Specialty Distribution recovers. Informally, the probability should compress to 15-25%. The Howden $50M attrition market also tightens: at the Q1 incremental pace of $10M, cumulative reaches $63M by Q4, above threshold; informally probability rises from 25% toward 35-45%.
The net thesis: classification remains price-below-value at $65.90, but with reduced conviction. The asymmetry has narrowed. Pre-earnings, the upside catalyst was Q1 cadence beat (now off the table) plus AI-disruption fear unwinding. Post-earnings, the upside catalysts are (a) Q2 organic stabilization above 2%, (b) Accession synergy realization through 2027-2028, (c) sustained buyback cadence deploying remaining $1.25B authorization. The downside floor is firmer: $250M Q1 buyback at depressed prices, 38.5% margin durability, $1.45B annualized CFO. The risk of a 'broken business' tail outcome has receded; the risk of a 'value trap' outcome (fair price, slow recovery) has risen.
Material open questions awaiting the Q1 2026 conference call (held 2026-04-28 8:00 AM EDT — transcript not yet in our delta sources): segment-level Accession revenue (informs the H1 miss market), FY26 organic guide reaffirm/revise, mgmt commentary on Howden disclosure cadence, and any change to the long-term margin target. The 10-Q (filed same day as 8-K) will provide segment-level organic and working capital detail that should refine the read.
At $65.90 (down 44% from prior peak), BRO trades at approximately 18-19x trailing earnings vs Marsh & McLennan and Aon at 22-25x. The Q1 results validate that the multiple compression captures real cyclical pressure, but the magnitude of margin/capital strength continues to disconnect from a permanent broken-business multiple. Re-rating now requires multiple quarters of evidence rather than a single cadence beat — making this a more classic value setup than a tactical mispricing trade.
Market Contributions7 markets
RESOLVED NO (Q1 2026 Organic Revenue grew 0.0% per 8-K filed 2026-04-27; final Brier 0.270). The ensemble's 52% prior probability proved too optimistic — Q1 was the seasonally easiest quarter (post-Q4 2025's -2.8% trough) and the failure to clear even 3% reveals continuing CAT property soft cycle pressure plus incremental Howden litigation drag ($10M Q1 carve-out from organic). This resolution materially escalates REVENUE_DURABILITY scrutiny: the 'modest improvement over 2.8%' framing is now under stress, and FY26 organic above 4% looks meaningfully harder than the prior 32% probability suggested.
ACTIVE — Q1 segment-level Accession revenue not disclosed in the press release; awaiting 10-Q deeper read and Q1 2026 conference call transcript. The press release noted $26M Acquisition/Integration Costs absorbed cleanly within margin guide, which is incrementally supportive but does not test the H1 miss thesis directly. Mgmt commentary in the press release was terse ('teammates continue to deliver in a challenging growth environment') — no FY26 guide reaffirm or revision. Probability remains anchored at 20% pending segment data; updates expected post-call.
ACTIVE — Q1 0.0% organic puts the FY26 above 4% threshold under significant pressure. To clear 4%, BRO would need average organic growth of ~5.3% across Q2-Q4 — a substantial acceleration from Q1's 0%. Achievable only if Howden runs off completely + CAT property pricing finds a floor + casualty rates stabilize at 3-6% + Specialty Distribution recovers. The 32% prior probability now looks too high; informally, post-Q1 probability likely 15-25%. Market remains active but trajectory is bearish. A Q2 organic below 2% would essentially close the door on FY26 above 4%.
ACTIVE — Q1 2026 adjusted EBITDAC margin 38.5% (vs 38.1% Q1 2025) provides 6.5 pts of cushion to the 32% FY threshold. Q1 is seasonally peak, but the 40 bps YoY expansion despite $26M Acquisition/Integration costs and the investment income reversal demonstrates the cumulative-headwind framing was somewhat overstated. The 84% prior probability looks well-founded; informally probability could rise to 88-92% post-Q1. Strongest single market validating the durability thesis post-earnings.
ACTIVE — Q1 2026 declared quarterly dividend of $0.165 (unchanged sequentially from Q4 2025). BRO's historical pattern is to announce annual dividend increases on the Q3 earnings call (October), so the unchanged Q1 dividend is fully consistent with the streak-continuation thesis. With $262M Q1 CFO + $1.45B FY25 baseline + $250M Q1 buyback executed alongside steady dividend, mgmt is signaling no constraint on continued capital return. 96% probability remains essentially the modal outcome.
ACTIVE — Q1 2026 repurchases of $250M is the most consequential single capital signal: 50% of the FY26 threshold deployed in a single quarter, signaling management's strong conviction that current valuation overshoots fundamentals. If Q2-Q4 cadence sustains even at $100M/quarter, FY26 reaches $550M. If the pace approximates $150M/quarter, FY26 exceeds $700M. Prior probability of 40% looks too low; informally, post-Q1 probability likely 70-85%. This market should likely be re-priced or near-resolved by Q2 print.
ACTIVE — Q1 2026 Litigation-Related Impact carve-out of $10M lifts cumulative to ~$33M against the $50M threshold. Q1 increment was larger than Q4 2025's marginal cadence, suggesting the injunction is slowing but not stopping migration. Three more quarters until resolution: at $10M/quarter pace, cumulative would reach $63M by Q4 2026 — above threshold. Probability now likely 35-45% (vs prior 25%) given the $10M Q1 incremental being persistent rather than one-time. Watch Q2 disclosure for trajectory.
Balancing Factors
Q1 2026 Adjusted EBITDAC margin 38.5% (+40 bps YoY) and Adjusted EPS $1.39 (+7.8%) confirm margin durability through cyclical organic pressure — FY26 ≥32% margin (84% probability) firmer than prior
Q1 2026 $250M share repurchases (50% of FY26 $500M market threshold in a single quarter) plus $1.5B authorization remaining signal high-conviction management capital deployment at depressed valuation
Q1 2026 operating cash flow $262M (+23% YoY) and FY25 baseline $1.45B confirm best-in-class 24% revenue conversion through the cyclical trough — FUNDING_FRAGILITY ROBUST reinforced
Quarterly dividend $0.165 declared (unchanged sequentially) consistent with annual increase on Q3 call; 33rd-streak continuation at 96% probability remains modal outcome
32-year dividend grower with founder-family alignment (Brown family ~10% beneficial ownership) and decentralized 24,000+ teammate culture remains structurally unique
Middle-market relationship brokerage moat (multi-line complexity, contingent commissions $74M Q1 vs $43M PY +$31M, state-by-state licensing) remains insulated from current-generation AI-native distribution targeting SME tail
Long-term margin target 32-37% remains intact and operationally on track — Q1 38.5% adjusted print is at the upper end of the range during peak quarter
Key Uncertainties
Q2 2026 organic recovery — Q2 print below 2% would mark two consecutive misses and crystallize the secular interpretation; above 3% would preserve cyclical framing. The single most decision-relevant near-term data point.
Q1 2026 conference call commentary not yet captured — FY26 guide reaffirm or revise, segment-level Accession revenue, Howden disclosure cadence outlook, long-term margin target reiteration
FY26 organic above 4% market (32% prior) — now appears materially less likely after Q1 0.0%; informally 15-25% post-Q1, depends on Howden runoff and CAT property floor
Howden cumulative attrition trajectory — Q1 added $10M (cumulative $33M); at this cadence, FY26 cumulative reaches $60M+ above the $50M market threshold
AI disruption catalyst path — middle-market commercial brokerage moat thesis remains intact post-Q1; carrier-direct AI distribution announcement targeting middle-market would still materially shift bear case
Accession integration through 2028 — Q1 segment-level Accession revenue not yet disclosed in press release; H1 miss market depends on Q2 print
Investment income reversal magnitude — Q1 investment and other income $21M vs $19M PY; not yet a material drag, but the FY headwind quantum remains uncertain ($30-80M range previously)
Three leadership changes (new Retail President, Barrett Brown leave, Mathis death) — no incremental disclosure in Q1 press release; status quo monitoring
Q1 0.0% organic narrowed the asymmetry. Upside catalysts now require: (a) Q2 2026 organic above 2% (preserves cyclical framing), (b) Q1 conference call FY26 guide reaffirmation, (c) sustained $100M+/quarter buyback cadence, (d) Howden cumulative attrition staying below $50M through Q4. Downside: a Q2 organic at-or-below 0% would crystallize the secular interpretation and shift assessment toward price-at-value. Margin durability and capital deployment have firmed the floor; the open question is whether the floor is at current price or 5-10% lower.
Confidence note: Confidence remains MEDIUM but for different reasons than 3 days ago. Pre-earnings, the load-bearing variable was Q1 cadence (now resolved bearish). Post-earnings, the load-bearing variable shifts to (a) Q2 2026 organic — whether mgmt's 'modest improvement' reads as H2-loaded or whether the secular interpretation is correct, (b) the Q1 2026 conference call commentary on FY26 guide and Accession synergy realization (not yet in our delta sources), and (c) Howden cumulative attrition trajectory ($33M against $50M threshold, with Q1 adding $10M — closer than baseline but still containable). Margin durability and capital deployment are now clearer floors — Q1's 38.5% adjusted EBITDAC margin with $250M buyback execution reduces tail risk on the durability markers. Confidence does not rise to HIGH because the H1 2026 secular-vs-cyclical question is genuinely unresolved; Q1 alone is not dispositive but the bear case is now empirically supported on the revenue line.
This assessment synthesizes probabilistic forecasts from an AI model ensemble for educational and informational purposes only. Model outputs may contain errors, hallucinations, or data lag. It does not constitute financial advice, a recommendation to buy or sell securities, or a guarantee of future outcomes. Past model performance does not predict future accuracy. Investors should conduct their own research and consult qualified financial advisors before making investment decisions.